ERBB2 and neoplasm: Additionally, mutations in oncogenes, such as KRAS [169], BRAF [170], and human epidermal growth factor receptor 2 (HER2) [171], can drive aberrant cell proliferation and survival signaling, thereby contributing to tumor relapse.